ArticleFrontiers in microbiology2012
Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.
Article in Frontiers in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Design of an epitope-based peptide vaccine against Cryptococcus neoformans.FEBS open bio · 2024Article
- Protective interaction of human phagocytic APC subsets withFrontiers in immunology · 2022Article
- Article
- Treatment strategies for cryptococcal infection: challenges, advances and future outlook.Nature reviews. Microbiology · 2021Review
- A Call to Arms: Quest for a Cryptococcal Vaccine.Trends in microbiology · 2018Review
- Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis.Frontiers in microbiology · 2017Review
- The Cell Biology of theFrontiers in cellular and infection microbiology · 2017Review
- Induction of Broad-Spectrum Protective Immunity against DisparateFrontiers in immunology · 2017Article
- Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome.Frontiers in microbiology · 2016Review
- Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.Cellular and molecular life sciences : CMLS · 2015Review
- Is Development of a Vaccine against Cryptococcus neoformans Feasible?PLoS pathogens · 2015Review
- Host immunity to Cryptococcus neoformans.Future microbiology · 2015Review
- Fungal vaccines and immunotherapeutics.Cold Spring Harbor perspectives in medicine · 2014Review
- Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii.Mycopathologia · 2014Article
- Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice.PloS one · 2014Article
- HIV and co-infections.Immunological reviews · 2013Review
- Vaccines and immunotherapy against fungi: the new frontier.Frontiers in microbiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cryptococcus neoformans and C. gattii, the predominant etiological agents of cryptococcosis, can cause life-threatening infections of the central nervous system in immunocompromised and immunocompetent individuals. Cryptococcal meningoencephalitis is the most common disseminated fungal infection in AIDS patients, and C. neoformans remains the third most common invasive fungal infection among organ transplant recipients. Current anti-fungal drug therapies are oftentimes rendered ineffective due to drug toxicity, the emergence of drug resistant organisms, and/or the inability of the host's immune defenses to assist in eradication of the yeast. Therefore, there remains an urgent need for the development of immune-based therapies and/or vaccines to combat cryptococcosis. Studies in animal models have demonstrated the efficacy of various vaccination strategies and immune therapies to induce protection against cryptococcosis. This review will summarize the lessons learned from animal models supporting the feasibility of developing immunotherapeutics and vaccines to prevent cryptococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.